196 related articles for article (PubMed ID: 26148572)
21. Spindle Cell Mucoepidermoid Carcinoma of the Palatine Tonsil With CRTC1-MAML2 Fusion Transcript: Report of a Rare Case in a 17-Year-Old Boy and a Review of the Literature.
Goh GH; Lim CM; Vanacek T; Michal M; Petersson F
Int J Surg Pathol; 2017 Dec; 25(8):705-710. PubMed ID: 28637362
[TBL] [Abstract][Full Text] [Related]
22. Role of CRTC1/MAML2 Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid Carcinoma.
Saade RE; Bell D; Garcia J; Roberts D; Weber R
JAMA Otolaryngol Head Neck Surg; 2016 Mar; 142(3):234-40. PubMed ID: 26796488
[TBL] [Abstract][Full Text] [Related]
23. CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast.
Bean GR; Krings G; Otis CN; Solomon DA; García JJ; van Zante A; Camelo-Piragua S; van Ziffle J; Chen YY
Histopathology; 2019 Feb; 74(3):463-473. PubMed ID: 30380176
[TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of mucoepidermoid carcinoma of the lung: 20 years' experience.
Yamamoto T; Nakajima T; Suzuki H; Tagawa T; Iwata T; Mizobuchi T; Yoshida S; Nakatani Y; Yoshino I
Asian Cardiovasc Thorac Ann; 2016 Mar; 24(3):257-61. PubMed ID: 26847635
[TBL] [Abstract][Full Text] [Related]
25. CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland.
Von Holstein SL; Fehr A; Heegaard S; Therkildsen MH; Stenman G
Oncol Rep; 2012 May; 27(5):1413-6. PubMed ID: 22323114
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
28. Reevaluation of MAML2 fusion-negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation.
Hsieh MS; Wang H; Lee YH; Ko JY; Chang YL
Hum Pathol; 2017 Mar; 61():9-18. PubMed ID: 27769871
[TBL] [Abstract][Full Text] [Related]
29. Primary mucoepidermoid carcinoma of the liver with CRTC1-MAML2 fusion: a case report.
Watanabe J; Kai K; Tanikawa K; Hiraki M; Mizukami N; Aishima S; Nakano T; Yamamoto H
Diagn Pathol; 2019 Jul; 14(1):84. PubMed ID: 31351495
[TBL] [Abstract][Full Text] [Related]
30. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
31. Sclerosing Mucoepidermoid Carcinoma in the Parotid Gland With CRTC1-MAML2 Fusion: A Case Report.
Yabuki K; Matsuyama A; Shiba E; Nagatani G; Hisaoka M
Int J Surg Pathol; 2018 May; 26(3):250-255. PubMed ID: 29169286
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
[TBL] [Abstract][Full Text] [Related]
33. Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor.
Ogasawara M; Nakamura Y; Morikawa N; Nitanai H; Moriguchi S; Chiba R; Saito H; Ohta M; Tanita T; Sugai T; Maeyama K; Yamauchi K; Takaoka Y
Cancer Chemother Pharmacol; 2016 May; 77(5):1019-29. PubMed ID: 27042857
[TBL] [Abstract][Full Text] [Related]
34. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
35. Fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography findings in a pediatric mucoepidermoid carcinoma and differential diagnosis.
Xie J; Ma C; Tang J
Hell J Nucl Med; 2017; 20(2):172-175. PubMed ID: 28697196
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.
Birkeland AC; Foltin SK; Michmerhuizen NL; Hoesli RC; Rosko AJ; Byrd S; Yanik M; Nor JE; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Oral Oncol; 2017 May; 68():5-8. PubMed ID: 28438292
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
38. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Lara-Guerra H; Chung CT; Schwock J; Pintilie M; Hwang DM; Leighl NB; Waddell TK; Tsao MS
Lung Cancer; 2012 May; 76(2):235-41. PubMed ID: 22112291
[TBL] [Abstract][Full Text] [Related]
39. Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma.
Okumura Y; Miyabe S; Nakayama T; Fujiyoshi Y; Hattori H; Shimozato K; Inagaki H
Histopathology; 2011 Jul; 59(1):90-7. PubMed ID: 21668476
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review.
Li X; Guo Z; Liu J; Wei S; Ren D; Chen G; Xu S; Chen J
Thorac Cancer; 2018 Feb; 9(2):316-323. PubMed ID: 29388384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
